Covered recipient · General Payments record
JONATHAN D CONDIT
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,078.37
117 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,078.37 | 117 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $716.84 | 23 |
| AbbVie Inc. | $440.45 | 38 |
| Lilly USA, LLC | $196.54 | 13 |
| PFIZER INC. | $134.01 | 7 |
| GlaxoSmithKline, LLC. | $66.66 | 4 |
| SANOFI-AVENTIS U.S. LLC | $65.52 | 4 |
| Amgen Inc. | $62.90 | 4 |
| Merck Sharp & Dohme Corporation | $47.77 | 3 |
| Otsuka America Pharmaceutical, Inc. | $43.13 | 2 |
| Mylan Specialty L.P. | $36.88 | 2 |
| Esperion Therapeutics, Inc. | $36.51 | 2 |
| Novo Nordisk Inc | $33.57 | 2 |
| Janssen Pharmaceuticals, Inc | $32.44 | 2 |
| E.R. Squibb & Sons, L.L.C. | $31.13 | 2 |
| Biohaven Pharmaceuticals, Inc. | $29.02 | 2 |
| IBSA Pharma Inc. | $20.00 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.65 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.80 | 1 |
| Horizon Therapeutics plc | $13.36 | 1 |
| Amneal Pharmaceuticals LLC | $12.76 | 1 |
| Currax Pharmaceuticals LLC | $11.27 | 1 |
| Kowa Pharmaceuticals America, Inc. | $11.16 | 1 |
Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JONATHAN D CONDIT
NPI 1194803189 · CMS profile ID 53678
Allopathic & Osteopathic Physicians / Family Medicine
MUNCIE, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1194803189?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JONATHAN D CONDIT, NPI 1194803189, CMS profile ID 53678. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194803189?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JONATHAN D CONDIT, NPI 1194803189, CMS profile ID 53678. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194803189?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JONATHAN D CONDIT, NPI 1194803189, CMS profile ID 53678, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1194803189?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
117 matching records · $2,078.37 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–117 of 117.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $8.40 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818575003 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.83 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829701853 | CMS |
| AbbVie Inc. | $3.83 | 02/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794280505 | CMS |
| AbbVie Inc. | $5.03 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794280503 | CMS |
| Lilly USA, LLC | $24.54 | 01/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818574149 | CMS |
| AbbVie Inc. | $18.37 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794280501 | CMS |
| PFIZER INC. | $16.43 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832587361 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.25 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829436741 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.61 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830064189 | CMS |
| GlaxoSmithKline, LLC. | $20.71 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802726549 | CMS |
| AbbVie Inc. | $10.57 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794280499 | CMS |
| AbbVie Inc. | $4.72 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794280497 | CMS |
| AstraZeneca Pharmaceuticals LP | $366.31 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829837131 | CMS |
| AbbVie Inc. | $8.31 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794280493 | CMS |
| AbbVie Inc. | $2.80 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794280495 | CMS |
| Novo Nordisk Inc | $15.82 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811045049 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.21 | 01/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829853263 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $244,689.08 | 25 |
| PY2024 | Recipient | $9,738.00 | 1 |
| PY2024 | Principal investigator | $311,143.82 | 111 |
| PY2023 | Recipient | $785.01 | 2 |
| PY2023 | Principal investigator | $442,970.32 | 391 |
| PY2022 | Recipient | $1,019.00 | 2 |
| PY2022 | Principal investigator | $111,080.23 | 402 |
| PY2021 | Recipient | $199.34 | 1 |
| PY2021 | Principal investigator | $65,228.29 | 211 |
| PY2020 | Principal investigator | $151,013.74 | 270 |
| PY2019 | Recipient | $1,004.74 | 11 |
| PY2019 | Principal investigator | $260,709.14 | 111 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
25 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694295 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 12/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220802636 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,366.17 | 11/21/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK RESEARCH DEPARTMENT | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C | No dispute reported | 06/30/2026 | 1190309140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694293 |
| Principal investigator 1 | Eli Lilly and Company | $4,655.00 | 10/10/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) | No dispute reported | 06/30/2026 | 1187874691 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $411.00 | 10/06/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK RESEARCH DEPARTMENT | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C | No dispute reported | 06/30/2026 | 1190308188 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 09/24/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 09/24/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 08/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 08/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 08/01/2025 | Non-covered Recipient Entity American Health Network Of Muncie | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220694283 |
| Principal investigator 1 | Eli Lilly and Company | $3,201.00 | 04/21/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187876211 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 04/21/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF INDIANA LLC | EX9924-4473 | No dispute reported | 06/30/2026 | 1213737439 |
| Principal investigator 1 | Novo Nordisk AS | $2,909.56 | 03/31/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF INDIANA LLC | EX9924-4473 | No dispute reported | 06/30/2026 | 1213718092 |
| Principal investigator 1 | Eli Lilly and Company | $157,877.42 | 03/04/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | TIRZEPATIDE STUDY OF RENAL FUNCTION IN PEOPLE WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES: FOCUS ON KIDNEY HYPOXIA IN RELATION TO FATTY KIDNEY DISEASE USING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING | No dispute reported | 06/30/2026 | 1187876237 |
| Principal investigator 1 | Eli Lilly and Company | $54.75 | 02/25/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) | No dispute reported | 06/30/2026 | 1187874449 |
| Principal investigator 1 | Eli Lilly and Company | $13,044.28 | 02/11/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187876559 |
| Principal investigator 1 | Eli Lilly and Company | $868.59 | 01/31/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | TIRZEPATIDE STUDY OF RENAL FUNCTION IN PEOPLE WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES: FOCUS ON KIDNEY HYPOXIA IN RELATION TO FATTY KIDNEY DISEASE USING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING | No dispute reported | 06/30/2026 | 1187880677 |
| Principal investigator 1 | Eli Lilly and Company | $260.00 | 01/31/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187880679 |
| Principal investigator 1 | Novo Nordisk AS | $2,250.00 | 01/31/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF INDIANA LLC | EX9924-4473 | No dispute reported | 06/30/2026 | 1213763479 |
| Principal investigator 1 | Eli Lilly and Company | $44,946.02 | 01/06/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187880671 |
| Principal investigator 1 | Eli Lilly and Company | $1,139.34 | 01/03/2025 | Non-covered Recipient Entity AMERICAN HEALTH NETWORK OF IN LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187874329 |